Literature DB >> 8610167

Successful expression of human factor IX following repeat administration of adenoviral vector in mice.

J Walter1, Q You, J N Hagstrom, M Sands, K A High.   

Abstract

Adenoviral vectors can direct high-level expression of a transgene, but, due to a host immune response to adenoviral antigens, expression is of limited duration, and repetitive administration has generally been unsuccessful. Exposure to foreign proteins beginning in the neonatal period may alter or ablate the immune response. We injected adult and neonatal (immunocompetent) CD-1 mice intravenously with an adenoviral vector expressing human blood coagulation factor IX. In both groups of mice, expression of human factor IX persisted for 12-16 weeks. However, in mice initially injected as adults, repeat administration of the vector resulted in no detectable expression of the transgene, whereas in mice initially injected in the neonatal period, repeat administration resulted in high-level expression of human factor IX. We show that animals that fail to express the transgene on repeat administration have developed high-titer neutralizing antibodies to adenovirus, whereas those that do express factor IX have not. This experimental model suggests that newborn mice can be tolerized to adenoviral vectors and demonstrates that at least one repeat injection of the adenoviral vector is possible; the model will be useful in elucidating the immunologic mechanisms underlying successful repeat administration of adenoviral vectors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8610167      PMCID: PMC39760          DOI: 10.1073/pnas.93.7.3056

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  21 in total

1.  Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration.

Authors:  M A Kay; A X Holterman; L Meuse; A Gown; H D Ochs; P S Linsley; C B Wilson
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

2.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.

Authors:  Y Yang; F A Nunes; K Berencsi; E E Furth; E Gönczöl; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

3.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.

Authors:  J F Engelhardt; X Ye; B Doranz; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

Review 4.  A practical guide to the evaluation and treatment of hemophilia.

Authors:  B Furie; S A Limentani; C G Rosenfield
Journal:  Blood       Date:  1994-07-01       Impact factor: 22.113

5.  Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.

Authors:  Y Dai; E M Schwarz; D Gu; W W Zhang; N Sarvetnick; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

6.  Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains.

Authors:  D Barr; J Tubb; D Ferguson; A Scaria; A Lieber; C Wilson; J Perkins; M A Kay
Journal:  Gene Ther       Date:  1995-03       Impact factor: 5.250

7.  Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus.

Authors:  S K Tripathy; E Goldwasser; M M Lu; E Barr; J M Leiden
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

8.  In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.

Authors:  M A Kay; C N Landen; S R Rothenberg; L A Taylor; F Leland; S Wiehle; B Fang; D Bellinger; M Finegold; A R Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

9.  Phenotypic correction of hypercholesterolemia in apoE-deficient mice by adenovirus-mediated in vivo gene transfer.

Authors:  S C Stevenson; J Marshall-Neff; B Teng; C B Lee; S Roy; A McClelland
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-04       Impact factor: 8.311

Review 10.  Mouse embryonic hematopoiesis.

Authors:  E Dzierzak; A Medvinsky
Journal:  Trends Genet       Date:  1995-09       Impact factor: 11.639

View more
  27 in total

1.  Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector.

Authors:  Federico Mingozzi; Jörg Schüttrumpf; Valder R Arruda; Yuhong Liu; Yi-Lin Liu; Katherine A High; Weidong Xiao; Roland W Herzog
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

2.  Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes.

Authors:  Zhijian Wu; Aravind Asokan; Joshua C Grieger; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; R Jude Samulski
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

Review 3.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

Review 4.  Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Nat Rev Genet       Date:  2011-05       Impact factor: 53.242

5.  Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.

Authors:  H Nakai; S R Yant; T A Storm; S Fuess; L Meuse; M A Kay
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

6.  Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.

Authors:  Jonathan D Finn; Daniel Hui; Harre D Downey; Danielle Dunn; Gary C Pien; Federico Mingozzi; Shangzhen Zhou; Katherine A High
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

7.  Novel caprine adeno-associated virus (AAV) capsid (AAV-Go.1) is closely related to the primate AAV-5 and has unique tropism and neutralization properties.

Authors:  Alejandra E Arbetman; Michael Lochrie; Shangzhen Zhou; Jennifer Wellman; Ciaran Scallan; Mohammad M Doroudchi; Britta Randlev; Susannah Patarroyo-White; Tongyao Liu; Peter Smith; Howard Lehmkuhl; Lea Ann Hobbs; Glenn F Pierce; Peter Colosi
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 8.  Engineering biomaterial systems to enhance viral vector gene delivery.

Authors:  Jae-Hyung Jang; David V Schaffer; Lonnie D Shea
Journal:  Mol Ther       Date:  2011-05-31       Impact factor: 11.454

9.  A single intravenous injection of adeno-associated virus serotype-9 leads to whole body skeletal muscle transduction in dogs.

Authors:  Yongping Yue; Arkasubhra Ghosh; Chun Long; Brian Bostick; Bruce F Smith; Joe N Kornegay; Dongsheng Duan
Journal:  Mol Ther       Date:  2008-09-30       Impact factor: 11.454

10.  Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells.

Authors:  Eric Dobrzynski; Julie C Fitzgerald; Ou Cao; Federico Mingozzi; Lixin Wang; Roland W Herzog
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.